FDAnews Drug Daily Bulletin

Xellia Acquires Fresenius Kabi’s Manufacturing Plant

July 9, 2014
Xellia Pharmaceuticals has acquired Fresenius Kabi’s lyophilized vial manufacturing facility in Raleigh, North Carolina. The manufacturing site is Xellia’s first facility in the U.S., expanding the company’s manufacturing capacity for injectable pharmaceutical products. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi USA.